[CPT - 11联合化疗治疗转移性胃癌]

[CPT-11 combined chemotherapy for metastatic gastric cancer].

作者信息

Narahara Hiroyuki, Sugimoto Naotoshi, Iishi Hiroyasu, Tatsuta Masaharu

机构信息

Department of Gastrointestinal Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka 537-8511, Japan.

出版信息

Gan To Kagaku Ryoho. 2004 Nov;31(12):1973-7.

PMID:15570923

Abstract

The effectiveness of chemotherapy for metastatic gastric cancer has been already revealed. But a standard chemotherapy has not been established yet. New agents such as TS-1, CPT-11 and taxanes are improving the response rates and also the survivals for gastric cancer. Including these new drugs, several randomized phase III trials are ongoing in Japan. In the near future, the candidate for standard resume will be sent abroad. In this article, we described the current state of CPT-11 combined chemotherapy for gastric cancer. Among various CPT-11- combined chemotherapy, CPT-11 + TS-1 is the most effective and less toxic treatment.

摘要

化疗对转移性胃癌的有效性已经得到证实。但尚未确立标准化疗方案。诸如替吉奥（TS-1）、伊立替康（CPT-11）和紫杉烷类等新型药物正在提高胃癌的缓解率及生存率。包括这些新药在内，日本正在进行多项III期随机试验。在不久的将来，标准治疗方案的候选药物将会推广至国外。在本文中，我们描述了CPT-11联合化疗治疗胃癌的现状。在各种CPT-11联合化疗方案中，CPT-11 + TS-1是最有效且毒性较小的治疗方法。